Opexa Therapeutics held a conference call Conference call to discuss the option and license agreement with Merck Serono for development of Tcelna for treatment of Multiple Sclerosis was held on February 5 at 8:30 am and has a webcasted replay available. Webcast Link
Opexa Therapeutics expects to submit IND for OPX-212 in mid 2015 Expects to initiate a Phase 1/2 clinical trial of OPX-212 in NMO for 2H15. Expects to apply for orphan drug designation and fast track designation for OPX-212 in 2016 or 2017. Expects to report top-line data of Abili-T Phase 2b trial of Tcelna in SPMS in 2H16.